Grail Stock
Blood-sampling device
About Grail Stock
Grail develops a pan-cancer screening test designed to detect cancer early. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. Jeffrey Huber and Sjuul van den Eertwegh founded Grail in 2016, with its headquarters in Menlo Park in California.
Investors
6 Dimensions Capital
Ally Bridge Group
ARCH Venture Partners
Grail, Codiak Biosciences, Aledade, Metacrine, Beam Therapeutics, Mindstrong Health
Blue Pool Capital
HuangPu River Capital
Funding History
| January 2016 | $85.0M |
|---|---|
| November 2017 | $1.2B |
| May 2018 | $300M |
| November 2019 | $250M |
Management
Chief Executive Officer
Hans Bishop
Chief Operating Officer & Chief Financial Officer
Matthew Young
Chief Scientific Officer
Alex Aravanis
Press
fiercebiotech - Feb, 18 2020
TechCrunch - Nov, 1 2017
TechCrunch - Jan, 6 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Grail or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
